ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Avara buys another drug formulation site

by Rick Mullin
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

Avara Pharmaceutical Services has agreed to acquire AstraZeneca’s Reims, France, manufacturing and distribution facility. It’s the pharma service firm’s second deal for finished-drug manufacturing capacity in recent weeks, following an agreement to purchase Glaxo­Smith­Kline’s solid-dose formulation plant in Aiken, S.C. With the addition of Reims, Avara will have eight sites in France, Puerto Rico, the U.K., Ireland, Italy, and the U.S. Drug industry veteran Tim Tyson launched Avara in 2015 with the purchase of a Merck & Co. formulation plant in Arecibo, P.R.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment